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Abstract
Widely-varying published and presented analyses of the Benchmark Evidence From South American Trials: Treatment of
Intracranial Pressure (BEST TRIP) randomized controlled trial of intracranial pressure (ICP) monitoring have suggested
denying trial generalizability, questioning the need for ICP monitoring in severe traumatic brain injury (sTBI), re-assessing
current clinical approaches to monitored ICP, and initiating a general ICP-monitoring moratorium. In response to this disso-
nance, 23 clinically-active, international opinion leaders in acute-care sTBI management met to draft a consensus statement to
interpret this study. A Delphi method–based approach employed iterative pre-meeting polling to codify the group’s general
opinions, followed by an in-person meeting wherein individual statements were refined. Statements required an agreement
threshold of more than 70% by blinded voting for approval. Seven precisely-worded statements resulted, with agreement levels
of 83% to 100%. These statements, which should be read in toto to properly reflect the group’s consensus positions, conclude that
the BEST TRIP trial: 1) studied protocols, not ICP-monitoring per se; 2) applies only to those protocols and specific study groups
and should not be generalized to other treatment approaches or patient groups; 3) strongly calls for further research on ICP
interpretation and use; 4) should be applied cautiously to regions with much different treatment milieu; 5) did not investigate the
utility of treating monitored ICP in the specific patient group with established intracranial hypertension; 6) should not change the
practice of those currently monitoring ICP; and 7) provided a protocol, used in non-monitored study patients, that should be
considered when treating without ICP monitoring. Consideration of these statements can clarify study interpretation.
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Publication of the Benchmark Evidence from South AmericanTrials: Treatment of Intracranial Pressure (BEST TRIP) tri-
al1 has resulted in significant controversy in the treatment of
severe traumatic brain injury (sTBI). This randomized controlled
trial of intracranial pressure (ICP)–based management versus
management guided by serial computed tomography (CT) im-
aging and clinical examination without ICP monitoring tested
the primary hypothesis that ‘‘a management protocol based on
the use of intracranial-pressure monitoring would result in re-
duced mortality and improved neuropsychological and func-
tional recovery at 6 months.’’ It reported no significant between-
group difference in morbidity or mortality measured at six
months post-injury. Publicly-presented interpretations of the
clinical implications of this study have ranged from statements
that the BEST TRIP trial is irrelevant to treatment in high-income
countries due to its being conducted in Latin American low-
income countries, through questioning of the indications for ICP
measurement, to calls for a moratorium on ICP monitoring.
Public health implications have included limitation of insurance
reimbursement for ICP monitors in Brazil. Interpretation also has
varied widely in published analyses.2–18
There is a paucity of studies amenable to resolving such con-
troversy in this area, as summarized in the Guidelines for the
Management of Severe Traumatic Brain Injury in Adults from the
Brain Trauma Foundation (BTF).19 Accordingly, a group consen-
sus statement would be valuable in addressing the interpretation of
this study, the only large-scale, high-quality randomized controlled
trial on the topic. To develop such consensus, a Delphi method–
based meeting occurred in Seattle Washington, on September 6–8,
2013. A committee (the authors’ group) was selected from inter-
national opinion leaders who are currently active in both bedside
patient management and clinical research. Two professional
meeting facilitators were employed to ensure that the pre- and intra-
meeting methods addressed all topics originated by the participants
during discussion, recorded and represented all whole- and small-
group discussions in the consensus process, reflected input from all
participants, and that the final statements accurately reflect unbi-
ased group writing, editing, and consensus ratification processes.
Before the meeting, three surveys were conducted to poll the
overall opinions of the group regarding the interpretation and im-
plications of the study. The collected responses were consolidated
into two ‘‘straw man’’ summations—‘‘What the BEST TRIP trial
showed’’ and ‘‘Interpretation of the BEST TRIP trial’’—which
were used to initiate whole-group and small-group discussions.
Summaries from these iterations were condensed into working
summary statements, which the group then discussed, refined and
subjected to iterative blinded voting, targeting a consensus agree-
ment of more than 70%. All issues felt relevant were developed into
statements, which were iterated to consensus. No minority or dis-
senting opinions arose to produce statements that were rejected due
to lack of consensus. Although the statement-generating nature of
this process may have been insensitive to such dissention, the
consensus figures reached for the final statements support strong
group agreement. This process produced the following set of con-
sensus statements:
Statement 1 (100% Consensus)
The BEST-TRIP trial compared two management protocols for
treatment of severe TBI: one involving ICP monitoring and the
other involving serial CT imaging and neurologic examination. It
was not a trial of ICP monitoring or the efficacy of ICP monitoring.
Statement 2 (100% Consensus)
For the collective group of severe TBI patients meeting BTF
criteria for ICP monitoring, the BEST TRIP trial found no differ-
ence in outcome between patients treated following ICP monitoring
and treatment according to current BTF guidelines and patients
treated according to a novel standardized protocol of sequential CT
imaging and clinical examination modeled on local standard of
care. As a consequence, this trial should be regarded as a study of
two methods of severe traumatic brain injury management. Ques-
tions regarding sample size remain a concern, particularly with
reference to the ability of this study to determine equivalence or
rule out treatment effects that are more subtle or specific to selected
patient subgroups.
Statement 3 (100% Consensus)
The primary impact of the BEST TRIP trial should be research
oriented, suggesting that further investigation is necessary in the
areas of selection of patients for ICP monitoring, determination of
patient-specific ICP thresholds, and development of treatment
methods and paradigms.
Statement 4 (94% Consensus)
The BEST TRIP trial is a study with high internal validity. The
external validity of the BEST TRIP trial is low, primarily due to
concerns regarding generalizability arising from unquantified un-
certainties surrounding the influence of the prehospital environ-
ment on the composition of the study group. Additional questions
arise from treatment options in the ICP group.
Statement 5 (94% Consensus)
ICP monitoring was tested in a broad group of patients with
severe TBI who did not all have intracranial hypertension. Thus, the
role of ICP monitoring in directing the treatment of established
intracranial hypertension was not a focus of the BEST TRIP trial.
Statement 6 (94% Consensus)
For those currently monitoring ICP, the results of the BEST
TRIP trial should not change their practice.
Statement 7 (83% Consensus)
This multicenter randomized trial also showed that the use of the
previously unstudied Imaging and Clinical Examination (ICE)
protocol in a hospital with limited economic resources that preclude
the availability of intracranial pressure monitoring may lead to non-
inferior clinical outcomes, compared with the BTF guidelines-
driven control of ICP using intracranial pressure monitoring.
The committee agreed that these statements represent the ag-
gregate opinion of the group.
It must be stressed that these statements reflect a consensus core
acceptable to all participants but not necessarily reflecting the
opinion of any individual author. Many differing opinions can be
woven around this core. Its main purpose is to orient the analytic
process upon the data as presented in the publication. It is expressly
not intended to inhibit varying analyses or define the range of
interpretations.
We hope that these statements will serve as a reference to
practicing physicians, researchers, and clinical associations in
guiding the interpretation of the BEST TRIP results and mitigating
what one committee member termed ‘‘collateral damage’’ from its
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misunderstanding. Further consensus recommendations are pres-
ently in preparation regarding clinical and research approaches to
ICP monitoring and treatment in light of current data.
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